Chronic Liver Disease (CLD)Phase 1NCT07521241
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults
A Phase 1 study testing AD-230, AD-2301 in people with Chronic Liver Disease (CLD), run by Addpharma Inc. at 1 site in South Korea.
Trial summary
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults Read more about this study
- Who is it for?
- Ages 19 to 64 yearsHealthy volunteers can take part
- Conditions the study is for
- Chronic Liver Disease (CLD)
- What is being tested?
- AD-230, AD-2301
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 52 participants
- Where
- 1 siteSouth Korea
- Study dates
- May 2026to Jul 2026
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 64 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- - Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit
- Subjects aged 19 years or older and under 65 years at the screening visit
Who cannot join
- Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
- Other exclusions applied
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site
Kyungpook National university hospital
Seoul
Young-Ran Yoon, +82-53-420-4950, yry@knu.ac.kr
About this study
Official title: A Randomized, Open-label, Two-treatment, Two-period, Two-sequence Crossover Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults
- Conditions
- Chronic Liver Disease (CLD)
- Being tested
- AD-230, AD-2301
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AD-230, AD-2301Drug
Oral administration of AD-230 or AD-2301, according to randomized sequence.
| Study group | Role | What they receive |
|---|---|---|
| Sequence A | Experimental | Period 1 : Reference drug(AD-2301), Period 2 : Test drug(AD-230) Single oral dose administration of AD-2301 three times in Period 1, followed by single oral dose administration of AD-230 twice in Period 2. Receives: Drug: AD-230, AD-2301 |
| Sequence B | Experimental | Period 1 : Test drug(AD-230), Period 2 : Reference drug(AD-2301) Single oral dose administration of AD-230 twice in Period 1, followed by single oral dose administration of AD-2301 three times in Period 2 Receives: Drug: AD-230, AD-2301 |
What is being measured
The primary outcome is the main question the study is designed to answer.
AUClast
Measured: -24hours to 72hours
Cmax
Measured: -24hours to 72hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Apr 2026
- Study startMay 2026 (estimated)
- Primary completionJun 2026 (estimated)
- Study completionJul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Liver Disease (CLD)Studies of the same condition, open and under way.
- More trials run by Addpharma Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 52 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Addpharma Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07521241
- Sponsor's protocol ID
- AD-230BE
- Status last verified
- Apr 2026
- First submitted
- 3 Apr 2026
- Last updated
- 13 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Open-label, Two-treatment, Two-period, Two-sequence Crossover Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults
- ClinicalTrials.gov ID
- NCT07521241
- Acronym / sponsor ID
- AD-230BE
- Conditions
- Chronic Liver Disease (CLD)
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 52 participants (estimated)
- Lead sponsor
- Addpharma Inc.Industry (pharma, biotech, devices)
- Study start
- May 2026 (estimated)
- Primary completion
- Jun 2026 (estimated)
- Study completion
- Jul 2026 (estimated)
- First posted
- 9 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sequence A | Experimental | Drug: AD-230, AD-2301Period 1 : Reference drug(AD-2301), Period 2 : Test drug(AD-230) Single oral dose administration of AD-2301 three times in Period 1, followed by single oral dose administration of AD-230 twice in Period 2. |
| Sequence B | Experimental | Drug: AD-230, AD-2301Period 1 : Test drug(AD-230), Period 2 : Reference drug(AD-2301) Single oral dose administration of AD-230 twice in Period 1, followed by single oral dose administration of AD-2301 three times in Period 2 |
Who may qualify
- Ages
- 19 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- - Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit
- Subjects aged 19 years or older and under 65 years at the screening visit
Key exclusion criteria (2 listed)
- Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
- Other exclusions applied
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AD-230, AD-2301Oral administration of AD-230 or AD-2301, according to randomized sequence. | Drug | Sequence A, Sequence B |
Primary outcome
AUClast
Time frame: -24hours to 72hours
Cmax
Time frame: -24hours to 72hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Chronic Liver Disease (CLD)
RecruitingPhase 4
Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)
Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency
Recruiting
EUS-guided Portal Pressure Gradient (PPG) Measurement: a Potential Alternative to the Traditional HVPG
Portal Hypertension, Chronic Liver Disease (CLD)
RecruitingObservational study
To Study the Clinical Course and Outcomes of Non-electively Hospitalised Patients of Chronic Liver Disease (CLD) With Hepatic or Extra-hepatic Predominant Organ Failure(s) at 6 Months.
Chronic Liver Disease
RecruitingPhase 4
Vitamin D2 vs Vitamin D2 Plus Calcitriol in Cholestatic Children With Vitamin D Deficiency
Cholestatic Liver Disease, Chronic Liver Disease (CLD)
Active, not recruitingObservational study
Identification of Patients With Advanced Chronic Diseases in Need of Palliative Care
Cancer, Chronic Liver Disease (CLD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing AD-230, AD-2301 in people with Chronic Liver Disease (CLD), run by Addpharma Inc. at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sarah Yoon (031-891-5576, sryoon@addpharma.co.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AUClast (time frame: -24hours to 72hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026.